ArticleCancer science2026

Perioperative Durvalumab for Resectable NSCLC: Updated Outcomes for Japanese Patients in AEGEAN.

Tetsuya Mitsudomi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.